Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab-Reference-Cited by-同舟云学术

Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab

Published:2022-12-14 Issue:7 Volume:12 Page:7772-7783
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Tada Toshifumi¹²^ORCID,Kumada Takashi³,Hiraoka Atsushi⁴^ORCID,Hirooka Masashi⁵,Kariyama Kazuya⁶^ORCID,Tani Joji⁷,Atsukawa Masanori⁸,Takaguchi Koichi⁹,Itobayashi Ei¹⁰,Fukunishi Shinya¹¹,Tsuji Kunihiko¹²,Ishikawa Toru¹³,Tajiri Kazuto¹⁴,Ochi Hironori¹⁵,Yasuda Satoshi¹⁶,Toyoda Hidenori¹⁶^ORCID,Ogawa Chikara¹⁷,Nishimura Takashi¹^ORCID,Hatanaka Takeshi¹⁸^ORCID,Kakizaki Satoru¹⁹,Shimada Noritomo²⁰,Kawata Kazuhito²¹,Tada Fujimasa⁴,Ohama Hideko⁴,Nouso Kazuhiro⁶,Morishita Asahiro⁷,Tsutsui Akemi⁹,Nagano Takuya⁹,Itokawa Norio⁸,Okubo Tomomi⁸,Arai Taeang⁸,Imai Michitaka¹³,Kosaka Hisashi²²,Naganuma Atsushi²³^ORCID,Koizumi Yohei⁵,Nakamura Shinichiro²,Kaibori Masaki²²,Iijima Hiroko¹,Hiasa Yoichi⁵^ORCID

Affiliation:

1. Division of Gastroenterology and Hepatology, Department of Internal Medicine Hyogo Medical University Nishinomiya Japan

2. Department of Internal Medicine Japanese Red Cross Himeji Hospital Himeji Japan

3. Department of Nursing Gifu Kyoritsu University Ogaki Japan

4. Gastroenterology Center Ehime Prefectural Central Hospital Matsuyama Japan

5. Department of Gastroenterology and Metabology Ehime University Graduate School of Medicine Ehime Japan

6. Department of Gastroenterology Okayama City Hospital Okayama Japan

7. Department of Gastroenterology and Hepatology Kagawa University Kagawa Japan

8. Division of Gastroenterology and Hepatology, Department of Internal Medicine Nippon Medical School Tokyo Japan

9. Department of Hepatology Kagawa Prefectural Central Hospital Takamatsu Japan

10. Department of Gastroenterology Asahi General Hospital Asahi Japan

11. Department of Gastroenterology Osaka Medical and Pharmaceutical University Osaka Japan

12. Center of Gastroenterology Teine Keijinkai Hospital Sapporo Japan

13. Department of Gastroenterology Saiseikai Niigata Hospital Niigata Japan

14. Department of Gastroenterology Toyama University Hospital Toyama Japan

15. Hepato‐biliary Center Japanese Red Cross Matsuyama Hospital Matsuyama Japan

16. Department of Gastroenterology and Hepatology Ogaki Municipal Hospital Ogaki Japan

17. Department of Gastroenterology Japanese Red Cross Takamatsu Hospital Takamatsu Japan

18. Department of Gastroenterology Gunma Saiseikai Maebashi Hospital Maebashi Japan

19. Department of Clinical Research National Hospital Organization Takasaki General Medical Center Takasaki Japan

20. Division of Gastroenterology and Hepatology Otakanomori Hospital Kashiwa Japan

21. Department of Hepatology Hamamatsu University School of Medicine Hamamatsu Japan

22. Department of Surgery Kansai Medical University Osaka Japan

23. Department of Gastroenterology National Hospital Organization Takasaki General Medical Center Takasaki Japan

Funder

Japan Society for the Promotion of Science

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.5535

Reference44 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference

3. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

4. Is atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma superior even to lenvatinib? A Matching‐Adjusted Indirect Comparison Target;Casadei‐Gardini A;Oncol,2021

5. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interleukin-7 Risk Allele, Lymphocyte Counts, and Autoantibodies for Prediction of Risk of Immune-Related Adverse Events in Patients Receiving Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma;Oncology;2024-07-30

2. Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab;Targeted Oncology;2024-04-30

3. Safety and Feasibility of Combining On-Demand Selective Locoregional Treatment with First-Line Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma;Current Oncology;2024-03-15

4. Germline predictors for bevacizumab induced hypertensive crisis in ECOG-ACRIN 5103 and BEATRICE;British Journal of Cancer;2024-02-12

5. Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma;Cancers;2023-10-30